Stay updated on Pembrolizumab for HNSCC Residual Disease Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for HNSCC Residual Disease Clinical Trial page.

Latest updates to the Pembrolizumab for HNSCC Residual Disease Clinical Trial page
- CheckyesterdayChange DetectedAdded the disease term 'Squamous cell carcinoma of the head and neck' and a Resources entry for Genetic and Rare Diseases Information Center.SummaryDifference0.2%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedRevision: v3.5.0 added and Revision: v3.4.3 removed. This appears to be a technical site update with no changes to trial content.SummaryDifference0.1%

- Check22 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check51 days agoChange DetectedAdded Revision: v3.4.2. Deleted the government funding lapse notice and related operating-status information (Revision: v3.4.1).SummaryDifference0.4%

- Check58 days agoChange DetectedAdded a site-wide notice about funding-related status and updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check65 days agoChange DetectedThe changes are minor UI and metadata updates, including a glossary toggle, updated QC-related labels such as 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0', and removal of older labels. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab for HNSCC Residual Disease Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for HNSCC Residual Disease Clinical Trial page.